文献速递脑血管病

利伐沙班与华法林在房颤相关轻型缺血性卒中超早期应用的随机临床试验

Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2017-01-01

本研究为多中心随机开放标签盲法终点2期试验,纳入195例房颤相关轻型急性缺血性卒中5天内患者,比较利伐沙班与华法林4周内预防早期复发卒中及颅内出血的安全性和有效性,结果显示两组主要终点无差异,利伐沙班缩短住院时间。

要点

  • 利伐沙班与华法林在主要终点(新发缺血灶或新发颅内出血)上无显著差异。
  • 两组临床缺血性卒中各1例,新发颅内出血均为无症状性出血转化。
  • 利伐沙班组住院时间中位数4.0天,短于华法林的6.0天。

核心结论

  • 在房颤相关轻型急性缺血性卒中患者中,利伐沙班与华法林的安全性和有效性相当。

研究设计与样本

  • 纳入195例房颤相关轻型卒中且5天内适合早期抗凝的患者,随机1:1接受利伐沙班或华法林治疗4周。
  • 183例完成随访MRI并纳入主要终点分析,利伐沙班组95例,华法林组88例。

主要发现

  • 主要终点(新发缺血病灶或新发颅内出血)在利伐沙班组47例(49.5%)、华法林组48例(54.5%),相对风险0.91(95%CI 0.69-1.20; P=.49)。
  • 新发缺血病灶:利伐沙班组28例(29.5%),华法林组31/87例(35.6%),相对风险0.83(95%CI 0.54-1.26; P=.38)。
  • 新发颅内出血:利伐沙班组30例(31.6%),华法林组25/87例(28.7%),相对风险1.10(95%CI 0.70-1.71; P=.68)。
  • 每组各发生1例临床缺血性卒中,所有新发颅内出血均为无症状性出血转化。
  • 住院时间中位数利伐沙班组4.0天(四分位距2.0-6.0),华法林组6.0天(四分位距4.0-8.0),P<.001。

关键数值与推荐

  • 利伐沙班用法:10 mg/d用5天,之后15或20 mg/d,共4周。
  • 华法林用法:目标INR 2.0-3.0,共4周。
  • 主要终点:4周MRI显示新发缺血病灶或新发颅内出血的复合终点。

临床怎么用

  • 对于房颤相关轻型急性缺血性卒中患者,可考虑超早期使用利伐沙班或华法林抗凝,两者安全性及有效性相当。
  • 利伐沙班可能有助于缩短住院时间。

局限性

  • 本研究为2期试验,样本量较小(195例随机,183例纳入分析)。
  • 开放标签设计,虽采用盲法终点评价,仍可能存在偏倚。
  • 研究仅纳入轻型卒中患者,结论不适用于中重度卒中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In atrial fibrillation (AF)-related acute ischemic stroke, the optimal oral anticoagulation strategy remains unclear. OBJECTIVE: To test whether rivaroxaban or warfarin sodium is safer and more effective for preventing early recurrent stroke in patients with AF-related acute ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: A randomized, multicenter, open-label, blinded end point evaluation, comparative phase 2 trial was conducted from April 28, 2014, to December 7, 2015, at 14 academic medical centers in South Korea among patients with mild AF-related stroke within the previous 5 days who were deemed suitable for early anticoagulation. Analysis was performed on a modified intent-to-treat basis. INTERVENTIONS: Participants were randomized 1:1 to receive rivaroxaban, 10 mg/d for 5 days followed by 15 or 20 mg/d, or warfarin with a target international normalized ratio of 2.0-3.0, for 4 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of new ischemic lesion or new intracranial hemorrhage seen on results of magnetic resonance imaging at 4 weeks. Primary analysis was performed in patients who received at least 1 dose of study medications and completed follow-up magnetic resonance imaging. Key secondary end points were individual components of the primary end point and hospitalization length. RESULTS: Of 195 patients randomized, 183 individuals (76 women and 107 men; mean [SD] age, 70.4 [10.4] years) completed magnetic resonance imaging follow-up and were included in the primary end point analysis. The rivaroxaban group (n = 95) and warfarin group (n = 88) showed no differences in the primary end point (47 [49.5%] vs 48 [54.5%]; relative risk, 0.91; 95% CI, 0.69-1.20; P = .49) or its individual components (new ischemic lesion: 28 [29.5%] vs 31 of 87 [35.6%]; relative risk, 0.83; 95% CI, 0.54-1.26; P = .38; new intracranial hemorrhage: 30 [31.6%] vs 25 of 87 [28.7%]; relative risk, 1.10; 95% CI, 0.70-1.71; P = .68). Each group had 1 clinical ischemic stroke, and all new intracranial hemorrhages were asymptomatic hemorrhagic transformations. Hospitalization length was reduced with rivaroxaban compared with warfarin (median, 4.0 days [interquartile range, 2.0-6.0 days] vs 6.0 days [interquartile range, 4.0-8.0]; P < .001). CONCLUSIONS AND RELEVANCE: In mild AF-related acute ischemic stroke, rivaroxaban and warfarin had comparable safety and efficacy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02042534.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 28892526. doi:10.1001/jamaneurol.2017.2161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。